<DOC>
	<DOCNO>NCT01099683</DOCNO>
	<brief_summary>A total 26 healthy elderly male female subject receive 10 mg NRL001 2 g rectal suppository placebo double-blind , cross-over study . The order treatment randomise , minimum washout period 3 day dos . An end study assessment conduct least 7 day administration last treatment . The pharmacokinetics NRL001 determine prior , , dose . Pharmacodynamics examine use three lead Holter monitor treatment period . Adverse Events , vital sign , ECGs clinical laboratory parameter collect , tabulate , review record throughout study .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacodynamic Pharmacokinetics Single Rectal Application 10 mg NRL001 Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Fecal Incontinence</mesh_term>
	<criteria>Volunteers include study satisfy follow criterion : Healthy adult male female volunteer ( determined medical history , physical examination , laboratory test value , vital sign electrocardiograms [ ECGs ] screen ) age ≥65 year . Nonsmokers 3 month receive first dose duration study . Body mass index ( BMI ) ≥ 18 ≤ 32 kg/m2 . Able willing receive rectal treatment . Able voluntarily provide write informed consent participate study . Sexually active male volunteer must use condoms partner throughout study 90 day completion study addition partner 's normal mode contraception . Male volunteer must donate sperm study 90 day completion study . Must understand purpose risk study agree follow restriction schedule procedure define protocol . Female volunteer must postmenopausal ( least 1 year , confirm FSH test screen ) . Must willing consent data enter The Over Volunteering Prevention System ( TOPS ) . The volunteer 's primary care physician must confirm nothing medical history would preclude enrolment clinical study . Volunteers exclude fulfil follow criterion : Positive HIV , hepatitis B , hepatitis C demonstrate result test screen . History presence significant cardiovascular , pulmonary , hepatic , renal , haematological , gastrointestinal ( GI ) , endocrine immunologic disease . History presence clinically significant anorectal condition judge Investigator ( e.g . concomitant enlarge symptomatic haemorrhoid acute presence anal fissure ) clinically significant drug allergy . Blood pressure excess 150/90 mmHg pulse rate 50 beat per minute screening . Any significant illness screen period precede entry study . Clinically relevant ECGabnormalities ( e.g . QTc prolongation , acute arrhythmia ) screen assessment Laboratory value abnormal deem clinically significant accord BioKinetic Europe Ltd. SOPs , unless agree advance Sponsor 's Responsible Medical Officer BioKinetic Investigator . Current history drug alcohol abuse positive drug abuse test screening check . Use disallow concomitant medication , include overthecounter item within 14 day prior study drug administration end study . Use medication apply via rectum , within 30 day prior dose Use medication currently within 30 day prior dose Investigator believe may affect study participation result . Participation clinical drug study 90 day precede initial dose study . Donation blood blood product within 90 day prior study drug administration , anytime study , except require protocol . History allergy medication , particularly nifedipine , α adrenoceptor antagonist latex Consumption alcoholic beverage within 24 hour prior dose period . Abstinence require study confinement . Consumption xanthinecontaining product within 24 hour dose period study confinement . Subjects consider competent consent trial fail Mini Mental State Exam ( MMSE ) . Volunteers , opinion Investigator , unsuitable participation study .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>